Coherus Oncology, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.16 | $-0.22 | -37.5% | Miss |
| Q12026 FY2026 | $-0.29 | $-0.27 | +6.9% | Beat |
| Q42025 FY2025 | $-0.38 | $-0.39 | -2.6% | Miss |
Back to CHRS overview · CHRS holders · CHRS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.